Selvita SA
WSE:SLV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
47.25
72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Selvita SA
Cash & Cash Equivalents
Selvita SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Selvita SA
WSE:SLV
|
Cash & Cash Equivalents
zł14.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Cash & Cash Equivalents
zł294k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Cash & Cash Equivalents
zł507.6k
|
CAGR 3-Years
194%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Cash & Cash Equivalents
zł176.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
41%
|
|
Selvita SA
Glance View
Selvita SA engages in the discovery, regulatory studies, as well as research and development. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 878 full-time employees. The company went IPO on 2019-10-16. The firm is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. The company offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The firm cooperates with numerous research institutes and universities from Europe and the United States.
See Also
What is Selvita SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
14.4m
PLN
Based on the financial report for Jun 30, 2024, Selvita SA's Cash & Cash Equivalents amounts to 14.4m PLN.
What is Selvita SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-38%
Over the last year, the Cash & Cash Equivalents growth was -61%. The average annual Cash & Cash Equivalents growth rates for Selvita SA have been -38% over the past three years .
You don't have any saved screeners yet
